BridgeMD
A multicentre, adaptive, randomised, multidomain, platform trial for dose optimization in the treatment of adult patients with haematological diseases (BLOOD-dose): core protocol
EU CTIS ID: 2026-525658-13-00
What this study is testing
The overall aim of the BLOOD-dose platform trial is to identify the optimal treatment intensity for patients with haematological diseases. Given the heterogeneity of haematological diseases, objectives, endpoints and estimands will differ across domains. The objectives for each domain will be described in the Domain-Specific Appendix. A core outcome set (COS) for haematological conditions consisting of in total 6 core outcome measurements has been established. Each domain is expected to include at least one core outcome measure as its primary endpoint, with all other core outcomes included as secondary endpoints. Thus, the main objective of a Domain-Specific Appendix could be to compare survival beween the interventions with the endpoint overall survival (OS), with the other 5 core outcome measures listed below as secondary objectives.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Participants of any sex who are at least 18 years of age at the time of providing informed consent.
- Participant diagnosed with a haematological disease, i.e. any disorder that primarily affects the blood, bone marrow, the lymphatic system and/or blood-forming organs.
- Eligible for participation in at least one of the currently active domains.
- Capable of giving signed informed consent for each applicable DSA(s). By consenting to a domain, participants also consent to participation in BLOOD-dose.
You likely can't join if
- The participant is expected to live less than 3 months, as judged by the investigator.
- Any condition that, in the opinion of the investigator, impairs the participant’s ability to understand trial procedures, provide informed consent and/or interfere with participation and/or compliance in the trial.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.